Wilfried Mullens, ESC 2022: Acetazolamide for acute decompensated heart failure, the ADVOR trial
The ADVOR trial reports the first positive findings for patients with acute decompensated heart failure (ADHF), seeing results in the cohort of patients receiving acetazolamide treatment. In this touchCARDIO interview, we speak with Professor Wilfried Mullens (Hasselt University, Hasselt, Belgium) to discuss the aim of the ADVOR trial in patients with ADHF and the implications of the findings for clinical practice.  Â
The abstract entitled ‘ADVOR – Acetazolamide in acute heart failure’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- Could you give us a brief overview of the limitations of current treatments for decompensated heart failure? (0:19)
- What are the aims and design of the ADVOR trial and how well were the primary and secondary outcome measures achieved? (0:53)
- What are the implications of these findings for clinical practice? (2:16)
Disclosures: Wilfried Mullens has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
